Physician profile
William B Nolan
NPI 1598815540
$838.72
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $338 · 2020: $221 · 2021: $164 · 2022: $116.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Epi Health, LLC | $105.43 | 2019-2022 | |
| Abbvie INC. | $97.19 | 2019-2020 | |
| Celgene Corporation | $81.62 | 2019 | |
| Almirall LLC | $76.74 | 2019-2021 | |
| Allergan, INC. | $59.55 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $57.50 | 2019 | |
| Genzyme Corporation | $52.81 | 2019-2021 | |
| Pfizer INC. | $44.45 | 2020 | |
| Merz North America, INC. | $43.69 | 2021 | |
| Amgen INC. | $36.85 | 2020-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $34.55 | 2019-2021 | |
| Lilly USA, LLC | $23.50 | 2021 | |
| Janssen Biotech, INC. | $23.10 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $20.90 | 2022 | |
| Vyne Pharmaceuticals INC. | $18.30 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermira, INC. | $17.16 | 2020 | |
| Mayne Pharma Commercial LLC | $16.83 | 2019 | |
| Journey Medical Corporation | $14.47 | 2020 | |
| Galderma Laboratories, L.P. | $14.08 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Nolan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.